Bamco Inc. NY Decreases Holdings in Schrödinger, Inc. (NASDAQ:SDGR)

Bamco Inc. NY trimmed its stake in Schrödinger, Inc. (NASDAQ:SDGR) by 90.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,000 shares of the company’s stock after selling 347,213 shares during the period. Bamco Inc. NY’s holdings in Schrödinger were worth $945,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of SDGR. Vanguard Group Inc. increased its stake in shares of Schrödinger by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,698,801 shares of the company’s stock worth $189,375,000 after purchasing an additional 28,981 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Schrödinger by 8.4% in the 4th quarter. SG Americas Securities LLC now owns 5,125 shares of the company’s stock worth $183,000 after purchasing an additional 397 shares in the last quarter. Raymond James & Associates increased its stake in shares of Schrödinger by 55.6% in the 4th quarter. Raymond James & Associates now owns 18,337 shares of the company’s stock worth $656,000 after purchasing an additional 6,552 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in Schrödinger in the 4th quarter worth $281,000. Finally, International Assets Investment Management LLC increased its stake in Schrödinger by 3,480.0% in the 4th quarter. International Assets Investment Management LLC now owns 1,790 shares of the company’s stock worth $64,000 after buying an additional 1,740 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Schrödinger Stock Down 0.9 %

Shares of Schrödinger stock traded down $0.20 during mid-day trading on Monday, hitting $22.22. The stock had a trading volume of 246,423 shares, compared to its average volume of 791,324. The firm has a 50-day moving average of $21.21 and a two-hundred day moving average of $24.62. Schrödinger, Inc. has a 12-month low of $18.21 and a 12-month high of $52.81. The firm has a market cap of $1.61 billion, a P/E ratio of -11.93 and a beta of 1.51.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). Schrödinger had a negative net margin of 75.94% and a negative return on equity of 29.25%. The business had revenue of $36.60 million during the quarter, compared to analysts’ expectations of $41.23 million. Sell-side analysts expect that Schrödinger, Inc. will post -2.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on SDGR. Citigroup cut their price target on Schrödinger from $39.00 to $37.00 and set a “buy” rating for the company in a research note on Thursday, May 2nd. Craig Hallum lowered their price target on shares of Schrödinger from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. KeyCorp reduced their price objective on shares of Schrödinger from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. SVB Leerink started coverage on shares of Schrödinger in a research report on Tuesday, July 2nd. They issued an “outperform” rating and a $29.00 price objective on the stock. Finally, Leerink Partnrs raised shares of Schrödinger to a “strong-buy” rating in a research report on Tuesday, July 2nd. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.90.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.